-Reuters
Omega Therapeutics’ Cancer Program Shows Encouraging Anti Tumor Activity In Liver Cancer
Omega Therapeutics Inc (NASDAQ: OMGA) announced preliminary data from the initial two dose level cohorts (n=8) from Part 1 of its Phase 1/2 MYCHELANGELO I study of OTX-2002 in hepatocellular carcinoma and other solid tumors associated